SCHEMBL2471298

SCHEMBL2471298

CN(C)S(=O)(=O)C(NC(=O)c1ccccc1O)C1(c2ccccc2)CCNCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.41
HPGD P15428 9/20 0.41
HSD17B10 Q99714 8/20 0.41
ALDH1A1 P00352 7/20 0.41
LMNA P02545 6/20 0.41
TSHR P16473 2/20 0.39
HTT P42858 5/20 0.34
TP53 P04637 3/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
GAA P10253 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
OPRM1 P35372 1/20 0.33
MPO P05164 1/20 0.33
HIF1A Q16665 1/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
POLB P06746 2/20 0.33
RCE1 Q9Y256 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2470910 0.88 POLB (0.38) HPGDALDH1A1LMNATP53MEN1
SCHEMBL2469390 0.87 P2RX1 (0.42) KDM4EHTTMEN1KMT2AOPRM1
SCHEMBL2468331 0.87 ALDH1A1 (0.44) HPGDALDH1A1MEN1KMT2ANPC1
SCHEMBL2468321 0.84 ALDH1A1 (0.44) HPGDALDH1A1MEN1KMT2ANPC1
SCHEMBL2469573 0.84 SMN1; SMN2 (0.36) KDM4EHPGDALDH1A1LMNAHTT
SCHEMBL2471159 0.83 SLC6A9 (0.36) ALDH1A1MEN1KMT2ASLC6A9MAPK1
SCHEMBL2469882 0.83 GAA (0.40) KDM4EALDH1A1KMT2AGAATDP1
SCHEMBL2469428 0.81 ALDH1A1 (0.44) HPGDALDH1A1MEN1KMT2ANPC1
SCHEMBL2469417 0.80 ALDH1A1 (0.36) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL2471276 0.79 ALDH1A1 (0.44) HPGDALDH1A1MEN1KMT2ASLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 KDM4E 485/4885HPGD 1527/4885HSD17B10 2641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.